13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001813845
Total reported value
$41.7M
$41.7M
6 檔
211.9%
In Q3 2025, BIOS Capital Management, LP's U.S. equity holdings reached a combined market value of $41.7M, distributed across 6 disclosed stock positions.
During Q3 2025, BIOS Capital Management, LP performed routine portfolio adjustments (0 new buys, 2 additions, 2 trims, and 0 full exits), keeping overall allocation balanced.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ACTU | Actuate Therapeutics Inc | Stock-Other | 75.62% | -15.19% | +0.85% | |
| 2 | CGTX | Cognition Therapeutics Inc | Stock-Other | 9.11% | +7.93% | — | |
| 3 | IRD | Opus Genetics Inc | Stock-Other | 7.42% | +4.63% | — | |
| 4 | LTRN | Lantern Pharma Inc | Stock-Other | 4.97% | +0.26% | -5.60% | |
| 5 | RNTX | Rein Therapeutics Inc | Stock-Other | 2.19% | +2.57% | — | |
| 6 | INABEUR | In8bio Inc | Stock-Other | 0.70% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | IRD | Opus Genetics Inc | +6.2% | — | Add |
| 2 | CGTX | Cognition Therapeutics Inc | +5.9% | — | Unchanged |
| 3 | LTRN | Lantern Pharma Inc | -0.4% | -5.60% | Trim |
| 4 | INABEUR | In8bio Inc | -1.1% | — | Trim |
| 5 | RNTX | Rein Therapeutics Inc | -1.6% | — | Unchanged |
| 6 | ACTU | Actuate Therapeutics Inc | -9% | +0.85% | Add |
According to official SEC Form 13F filings, BIOS Capital Management, LP reported a total U.S. public equity portfolio value of $41.7M across 6 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ACTU, CGTX, IRD) accounted for 211.9% of total reported equity market value during Q3 2025.
Top Position Liquidated / Trimmed
LTRN
前期市值: $4.3M
During Q3 2025, BIOS Capital Management, LP's top holdings by market value included ACTU (75.6%)、CGTX (9.1%)、IRD (7.4%). The largest single position, ACTU, represented 75.6% of total portfolio value.
In Q3 2025, BIOS Capital Management, LP made 4 total portfolio adjustments, initiating 0 new buys, adding to 2 positions, trimming 2 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.